Wen-Jing Wang1, Zhen Tao, Wei Gu, Li-Hua Sun. 1. Department of Infectious Diseases, Nanjing First Hospital, Nanjing Medical University, Nanjing, China E-mail : tz1010@126.com.
Abstract
OBJECTIVES: To study variation in T lymphocyte subgoups and its clinical significance in non-small cell lung cancer (NSCLC). METHODS: Levels of CD3+ , CD4+ , CD8+ , CD4+/CD8+, NK and Treg cells in peripheral blood of NSCLC cases and healthy adults were determined by flow cytometry. RESULTS: CD3+ , CD4+ and CD4+/CD8+ ratio and NK cells in NSCLCs were decreased significantly in comparison with the control group (P < 0.01), and decreased with increase in the clinical stage of NSCLC, while CD8+ cells demonstrated no significant change (P > 0.05). Treg cells were significantly more frequent than in the control group (P < 0.01), and increased with the clinical stage of NSCLC. CONCLUSION: The cellular immune function of the NSCLC patients is lowered. It is important to detect change of T lymphocyte subgroups by flow cytometry for the diagnosis, treatment and prognostic assessment of NSCLC patients.
OBJECTIVES: To study variation in T lymphocyte subgoups and its clinical significance in non-small cell lung cancer (NSCLC). METHODS: Levels of CD3+ , CD4+ , CD8+ , CD4+/CD8+, NK and Treg cells in peripheral blood of NSCLC cases and healthy adults were determined by flow cytometry. RESULTS: CD3+ , CD4+ and CD4+/CD8+ ratio and NK cells in NSCLCs were decreased significantly in comparison with the control group (P < 0.01), and decreased with increase in the clinical stage of NSCLC, while CD8+ cells demonstrated no significant change (P > 0.05). Treg cells were significantly more frequent than in the control group (P < 0.01), and increased with the clinical stage of NSCLC. CONCLUSION: The cellular immune function of the NSCLCpatients is lowered. It is important to detect change of T lymphocyte subgroups by flow cytometry for the diagnosis, treatment and prognostic assessment of NSCLCpatients.
Authors: Johanna Waidhauser; Pia Nerlinger; Tim Tobias Arndt; Stefan Schiele; Florian Sommer; Sebastian Wolf; Phillip Löhr; Stefan Eser; Gernot Müller; Rainer Claus; Bruno Märkl; Andreas Rank Journal: Cancer Immunol Immunother Date: 2021-12-20 Impact factor: 6.630